Inspire Investing LLC Buys Shares of 22,979 Enovis Corporation $ENOV

Posted by Brian Himes on Jul 3rd, 2026

Inspire Investing LLC bought a new position in Enovis Corporation (NYSE:ENOV – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 22,979 shares of the company’s stock, valued at approximately $523,000.

A number of other large investors have also made changes to their positions in ENOV. California State Teachers Retirement System increased its position in shares of Enovis by 1.2% during the 2nd quarter. California State Teachers Retirement System now owns 51,713 shares of the company’s stock valued at $1,622,000 after purchasing an additional 621 shares during the last quarter. MGO One Seven LLC boosted its holdings in shares of Enovis by 9.4% in the fourth quarter. MGO One Seven LLC now owns 7,581 shares of the company’s stock worth $202,000 after buying an additional 650 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after buying an additional 707 shares during the period. Empowered Funds LLC grew its position in Enovis by 13.0% during the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after buying an additional 749 shares during the period. Finally, Inscription Capital LLC increased its holdings in Enovis by 9.4% during the fourth quarter. Inscription Capital LLC now owns 11,869 shares of the company’s stock valued at $316,000 after buying an additional 1,016 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Enovis

In other news, insider Oliver Engert bought 1,200 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was bought at an average price of $21.62 per share, with a total value of $25,944.00. Following the acquisition, the insider owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This represents a 2.37% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders have acquired 4,200 shares of company stock worth $92,084. 2.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. BTIG Research reiterated a “buy” rating and issued a $39.00 price target on shares of Enovis in a research report on Friday, May 22nd. Wall Street Zen lowered Enovis from a “buy” rating to a “hold” rating in a research note on Sunday, June 28th. Zacks Research cut Enovis from a “hold” rating to a “strong sell” rating in a report on Tuesday. Wells Fargo & Company decreased their target price on Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Finally, Evercore reissued an “outperform” rating and set a $36.00 price target on shares of Enovis in a report on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Enovis presently has a consensus rating of “Moderate Buy” and an average price target of $44.50.

Check Out Our Latest Analysis on Enovis

Enovis Price Performance

Shares of NYSE:ENOV opened at $22.60 on Friday. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.04 and a quick ratio of 1.05. Enovis Corporation has a 1-year low of $19.14 and a 1-year high of $36.82. The company has a market capitalization of $1.30 billion, a P/E ratio of -1.14 and a beta of 1.39. The firm’s 50 day simple moving average is $23.25 and its two-hundred day simple moving average is $23.87.

Enovis (NYSE:ENOV – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, topping analysts’ consensus estimates of $0.82 by $0.07. The business had revenue of $589.15 million during the quarter, compared to analyst estimates of $572.02 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The company’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Research analysts expect that Enovis Corporation will post 3.12 EPS for the current fiscal year.

Enovis Company Profile

(Free Report)

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.